Identification of inherited genetic variations influencing prognosis in early-onset breast cancer

Cancer Research

Volumn 73, Issue 6, 2013, Pages 1883-1891

  Rafiq, Sajjad ^a   Tapper, William ^a   Collins, Andrew ^a   Khan, Sofia ^d   Politopoulos, Ioannis ^a   Gerty, Sue ^b   Blomqvist, Carl ^d   Couch, Fergus J ^c   Nevanlinna, Heli ^d   Liu, Jianjun ^e   Eccles, Diana ^b  

^a Genetic Epidemiology and Bioinformatics Research Group   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RETINOID RELATED ORPHAN RECEPTOR ALPHA; TRANSCRIPTION FACTOR PBX1;

ABCD1 GENE; ADULT; ARRDC3 GENE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; EARLY CANCER; FOLLOW UP; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NTN1 GENE; PBX1 GENE; PRIORITY JOURNAL; RORALPHA GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SYT6 GENE; TUMOR SUPPRESSOR GENE;

AGE OF ONSET; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84875453170     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3377     Document Type: Article

References (37)

1. http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/#age
2. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, et al. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 2005;103:2466-72.
3. Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer 1996;74: 1796-800.
4. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008;26:3324-30.
5. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea-a report from the Korean Breast Cancer Society. J Clin Oncol 2007;25:2360-8.
6. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006;6:194.
7. Hartman M, Lindstrom L, Dickman PW, Adami HO, Hall P, Czene K. Is breast cancer prognosis inherited? Breast Cancer Res 2007;9:R39.
8. Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 2011;48:520-2.
9. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, et al. BRCA1 testing should be offered to individuals with triplenegative breast cancer diagnosed below 50 years. Br J Cancer 2012;106:1234-8.
10. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010;42:504-7.
11. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, et al.Acommon variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011;43:1210-4.
12. Azzato EM, Pharoah PD, Harrington P, Easton DF, Greenberg D, Caporaso NE, et al. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers Prev 2010;19:1140-3.
13. Shu XO, Long J, Lu W, Li C, Chen WY, Delahanty R, et al. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res 2012;72:1182-9.
14. Tapper W, Hammond V, Gerty S, Ennis S, Simmonds P, Collins A, et al. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 2008;10:R108.
15. Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, et al. The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet 2012;21:3926-39.
16. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG, et al. Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer 2007;7:160.
17. Wang K, Li WD, Zhang CK, Wang Z, Glessner JT, Grant SF, et al. A genome-wide association study on obesity and obesity-related traits. PLoS ONE 2011;6:e18939.
18. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, et al. NAD(P)H:quinone oxidoreductase 1 NQO1&z.ast;2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008;40:844-53.
19. Li J,Humphreys K, Heikkinen T, Aittomaki K, Blomqvist C, Pharoah PD, et al. A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 2011;126:717-27.
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75.
21. http://www.kbioscience.co.uk/genotyping/genotyping-chemistry.html
22. http://www.genabel.org/
23. Harri R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. metan: fixed- and random-effects meta-analysis. Stata J 2008;8:3-28.
24. http://www.sph.umich.edu/csg/abecasis/MACH/index.html
25. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010;26:2336-7.
26. Nica AC, Parts L, Glass D, Nisbet J, Barrett A, Sekowska M, et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet 2011;7:e1002003.
27. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933-42.
28. Draheim KM, Chen HB, Tao Q, Moore N, Roche M, Lyle S. ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta4. Oncogene 2010;29:5032-47.
29. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res 2007;67:11565-75.
30. Huang CN, Huang SP, Pao JB, Chang TY, Lan YH, Lu TL, et al. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol 2012;23:707-13.
31. Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res 2010;12:R21.
32. Pallavi SK, Ho DM, Hicks C, Miele L, Artavanis-Tsakonas S. Notch and Mef2 synergize to promote proliferation and metastasis through JNK signal activation in Drosophila. EMBO J 2012;31: 2895-907.
33. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, et al. SCAN: SNP and copy number annotation. Bioinformatics 2010;26:259-62.
34. Magnani L, Ballantyne EB, Zhang X, Lupien M. PBX1 genomic pioneer function drives ERalpha signaling underlying progression in breast cancer. PLoS Genet 2011;7:e1002368.
35. Xiong G, Wang C, Evers BM, Zhou BP, Xu R. RORalpha suppresses breast tumor invasion by inducing SEMA3F expression. Cancer Res 2012;72:1728-39.
36. Forman BM, Chen J, Blumberg B, Kliewer SA, Henshaw R, Ong ES, et al. Cross-talk among ROR alpha 1 and the Rev-erb family of orphan nuclear receptors. Mol Endocrinol 1994;8:1253-61.
37. Ramesh G, Berg A, Jayakumar C. Plasma netrin-1 is a diagnostic biomarker of human cancers. Biomarkers 2011;16:172-80.